Resources

Implications for Shipping Clinical Materials into the European Market

Recently, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mould on paracetamol (acetaminophen) tablets

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex

EU Good Manufacturing Practice ANNEX 13 Investigational Medicinal Products

Can you imagine working for months to ensure your clinical supply strategy is in place for your European studies, only to have them be delayed because labeling requirements were out of compliance, and the QP or the site(s) rejected the materials you

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective

High Potency Drugs – from Molecule to Market

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30

Patient Centric Clinical Trials

Making Clinical Trials More Effective By Keeping Focus On The Patient - A Q&A with Justin Schroeder, Executive Director, Marketing, Business Development and Design, PCI Pharma Services

When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?

Your bridge between life-changing therapies and patients